Browse the range, or let the 2-minute quiz build your protocol.
An honest comparison of NMN and NR — two NAD+ precursors with different structures, different research histories and, in the UK, a different regulatory status. We sell NMN. NR wins some rows anyway, and we say so.
Food supplement ingredient guide · Not medical advice · No health claimsBoth are NAD+ precursors and vitamin B3 derivatives; NMN carries a phosphate group NR lacks. Inside the cell NR is phosphorylated to NMN, which is then converted to NAD+. NMN has the larger recent human research base (30+ studies, including a 2023 systematic review of 10 RCTs with 437 participants). NR has the longer safety record and, in the UK, the clearer legal position: nicotinamide riboside chloride is an authorised novel food, while NMN's application is still under assessment. Neither has an authorised health claim.
NR: nicotinamide riboside chloride is an authorised novel food in Great Britain (carried over from the EU authorisation) with conditions of use including a maximum daily level in food supplements. NMN: widely sold but not yet authorised — a GB novel food application for β-NMN (FSA reference RP-2116) is under assessment; EFSA published a positive safety opinion in the EU in 2026, with formal authorisation still pending and not binding in GB. No health claim is authorised for either compound. We sell NMN and we are not going to pretend this row is a draw.
NMN and NR are both NAD+ precursor food supplement ingredients — compounds the body can use to make NAD+, the coenzyme present in every living cell. See our What is NAD+? guide →
They are compared constantly because they feed the same salvage pathway, but they are structurally distinct compounds with different research histories and, in the UK, different regulatory positions. NR was commercialised first (as the branded ingredient Niagen) and went through the EU novel food process; NMN's research base grew later and faster.
Important: Neither compound has an authorised health claim in the UK or EU. This guide describes published research as factual information — not health claims for any product.
The structural difference is one phosphate group. NR lacks it; NMN has it. Inside the cell, NR must be phosphorylated to NMN before NMNAT enzymes can convert it to NAD+. So on paper: NR → NMN → NAD+ (2 steps) versus NMN → NAD+ (1 step).
The catch: published research indicates that much orally taken NMN is dephosphorylated to NR outside the cell (by the enzyme CD73) before being taken up, then rephosphorylated inside it. A proposed direct NMN transporter (Slc12a8) has been reported in mice but is contested. So the "one step closer" argument, which most NMN marketing (ours included, historically) leans on, is chemically true and practically unproven in humans.
Having one fewer conversion step does not automatically make NMN more effective. Cellular uptake, bioavailability and tissue distribution all matter, and the published research on both compounds continues to investigate them. What both compounds have shown in human trials is a measurable rise in blood NAD+. See NAD+ & Cellular Energy →
Bold marks the genuine advantage in each row. Some go to NR. Neither compound has an authorised health claim in the UK or EU.
| Property | NMN | NR |
|---|---|---|
| Full name | Nicotinamide Mononucleotide | Nicotinamide Riboside |
| Vitamin B3 derivative | Yes | Yes |
| Phosphate group | Yes | No (added inside the cell) |
| Steps to NAD+ (chemical) | 1 step | 2 steps |
| Steps to NAD+ (practical) | Unproven — much oral NMN converts to NR first | 2 steps |
| Recent human trial base | 30+ studies; systematic review of 10 RCTs (437 participants) | Multiple RCTs since 2016; smaller recent volume |
| Length of human safety record | Since ~2016 | Longer — doses to 2000mg/day studied |
| Doses in human research | 250–900mg/day (one 4-week study at 1250mg) | 100–2000mg/day |
| GB novel food status | Application RP-2116 under assessment | Authorised (nicotinamide riboside chloride) |
| EU status (Sep 2026) | EFSA positive opinion 2026; authorisation pending | Authorised |
| Authorised health claims (UK/EU) | None | None |
| Combination formulas widely available | Yes — with resveratrol, TMG, pterostilbene, apigenin | Fewer |
| Available from Vitality | Yes — four formulas | No |
Both compounds have substantial published research. The following describes it by study design, not outcome — summarising outcomes as benefits would be a health claim. Full research references →
NMN's human research base has grown rapidly since 2016. A 2023 systematic review (Yi et al., GeroScience) covering 10 randomised controlled trials with 437 participants pooled blood NAD+ and adverse-event data at doses from 250 to 900mg per day; no significant adverse events were reported. See the NMN dosage guide for the study-by-study table.
NR's human trials began slightly earlier and cover a wider dose range — 100mg up to 2000mg per day — across healthy adults, older adults and clinical populations. Published NR trials have measured blood NAD+ and a range of safety and physiological endpoints. NR's longer commercial history (as the branded ingredient Niagen) also means a longer post-market safety record, which is part of why it completed the novel food process first.
NMN has more recent human trials and the only systematic review of RCTs between the two. NR has the longer and wider safety dataset. Neither fact is a health claim, and no head-to-head human trial establishes one as more effective than the other.
NMN has the bigger recent trial base. NR has the longer safety record and the GB authorisation. Both are true at once.
Both are legitimate NAD+ precursor supplement ingredients. Decide on what matters to you. For NMN-specific quality criteria: how to choose an NMN supplement →
>99% β-NMN purity · ISO/IEC 17025 tested every batch · UK manufactured · CoA on request